RELEASE DETAILS

WALTHAM, Mass.--(BUSINESS WIRE)--Aug. 8, 2018-- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of product candidates using its proprietary mucus-penetrating particle (MPP) technology, today announced that it will present at the 2018 Wedbush PacGrow Healthcare Conference in New York, NY. Mark Iwicki, Chairman and Chief Executive Officer at Kala Pharmaceuticals, will provide a corporate overview on Wednesday, August 15, 2018 at 9:45 AM ET.

To access a live webcast and subsequent archived recording of the presentation, please visit “Events” in the “Investors” section of the Kala website at http://kalarx.com/.

About Kala

Kala is a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary mucus-penetrating particle (MPP) technology, with an initial focus on the treatment of eye diseases. Kala has applied the MPP technology to a corticosteroid designed for ocular applications, resulting in two lead product candidates: INVELTYS™ (KPI-121 1%) for the treatment of inflammation and pain following ocular surgery, for which an NDA has been accepted for review by the FDA and given a target action date under the Prescription Drug User Fee Act (PDUFA) of August 24, 2018, and KPI-121 0.25% for the temporary relief of the signs and symptoms of dry eye disease.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180808005660/en/

Source: Kala Pharmaceuticals, Inc.

For Kala Pharmaceuticals, Inc.
Investor Contact
Michael Schaffzin, 212-362-1200
michael@sternir.com